1. Home
  2. CFND vs NNVC Comparison

CFND vs NNVC Comparison

Compare CFND & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

HOLD

Current Price

$3.51

Market Cap

23.8M

Sector

N/A

ML Signal

HOLD

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.72

Market Cap

21.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
NNVC
Founded
N/A
2005
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.8M
21.2M
IPO Year
2025
2008

Fundamental Metrics

Financial Performance
Metric
CFND
NNVC
Price
$3.51
$1.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.1K
971.2K
Earning Date
N/A
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$0.85
52 Week High
$9.67
$2.23

Technical Indicators

Market Signals
Indicator
CFND
NNVC
Relative Strength Index (RSI) 45.67 60.21
Support Level $3.18 $1.26
Resistance Level $4.14 $1.87
Average True Range (ATR) 0.22 0.18
MACD 0.02 0.01
Stochastic Oscillator 61.40 64.94

Price Performance

Historical Comparison
CFND
NNVC

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: